Status:
UNKNOWN
Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases
Lead Sponsor:
Universidade Estadual de Londrina
Collaborating Sponsors:
Universidade Norte do Paraná
Conditions:
Interstitial Lung Disease
Eligibility:
All Genders
40-75 years
Brief Summary
This prospective cohort study will investigate whether progression of the interstitial lung diseases is related to specific clinical endpoints and their changes over time. Longitudinal data of patient...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with interstitial lung disease:
- Age between 40 and 75 years old upon inclusion;
- Diagnosis of interstitial lung disease;
- Clinical stability for at least 4 weeks prior to inclusion;
- Absence of any comorbidity that interferes with the performance of tests;
- Age-matched control group:
- Age between 40 and 75 years old upon inclusion;
- Absence of any comorbidity that interferes with the performance of tests;
- Exclusion Criteria (both groups):
- Participants that present severe or unstable cardiac disease identified during the cardiopulmonary exercise testing;
- Participants with cognitive deficit that interfere with any of the tests;
Exclusion
Key Trial Info
Start Date :
September 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT03400839
Start Date
September 15 2017
End Date
October 1 2023
Last Update
August 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidade Estadual de Londrina
Londrina, Paraná, Brazil, 86038-350